Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes

Curcumin Supplementation and Type 2 Diabetes

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02529969

Enrollment

Registered

2015-08-20

Start date

2015-07-31

Completion date

Unknown

Last updated

2015-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Insulin Dependent Diabetes

Brief summary

Diabetes mellitus is the most common endocrine disorder, causes many complications such as micro- and macro-vascular diseases. Various kinds of antidiabetic drugs have been developed, but most of them have side effects. Recently, the use of natural plant products has gained more attention among scientists in order to prevent diabetic vascular complications. Curcumin is a natural yellow product derived from the turmeric rhizome which has shown to be non-toxic and exhibits various bio¬logical activities such as anti-oxidant, anti-inflammatory, anti-carcinogenic, and anti-diabetic effects. Curcumin is effective in reducing glycemic index and hyperlipidemia in rodent models and is relatively inexpensive and safe. Most of the studies conducted on animal model, and just a few of them are on human model. The present study was planned to evaluate the effects of curcumin supplementation on serum levels of lipid profile and inflammatory markers in patients with type 2 diabetes

Interventions

DIETARY_SUPPLEMENTcurcumin

DIETARY_SUPPLEMENTPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Tendency to participate 2. Age range of 40-65 3. Suffering from diabetes type 2 ( between 1 to 10 yeares) 4. BMI 18/5-30 5. Patients with diabetes who administer oral hypoglycemic agents and do not use

Exclusion criteria

1. patients with liver diseases 2. patients with kidney diseases 3. patients with inflammatory diseases 4. patients with liver diseases 5. Administering herbal agents 6. Administering multivitamins and minerals in past 3 months

Design outcomes

Primary

Measure	Time frame
Triglyceride	12 weeks

Secondary

Measure	Time frame
C-Reactive Protein	12 weeks

Countries

Iran

Contacts

Primary ContactGolbon Sohrab

golbonsohrab@yahoo.com+98-21-22077424

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026